FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3029619171> ?p ?o ?g. }

• W3029619171 endingPage "646" @default.
• W3029619171 startingPage "641" @default.
• W3029619171 abstract "ObjectiveTo investigate calreticulin (CALR) gene mutations classification in BCR-ABL1 negative myeloproliterative neoplasms (MPN), and its relationship with clinical manifestations.MethodsGenomic DNA polymerase chain reaction (PCR) amplification product Sanger sequencing method was used to detect the mutation of exon 9 of CALR gene in 236 patients with BCR-ABL1 negative MPN (excluding polycythemia vera and negative CALR mutations) in Ruijin Hospital of Shanghai Jiao Tong University School of Medicine from November 2015 to November 2018. The mutations were classified into 52 bp deletion (type 1) mutation, 5 bp insertion (type 2) mutation and other mutation types according to PCR sequencing analysis. The clinical characteristics of the carriers with two kinds of mutations in 198 patients with essential thrombocythemia (ET) and 38 primary myelofibrosis (PMF) were compared. For the types of mutations that could not be determined, they were classified according to the α-helix propensity score of the mutant protein peptide chain or the degree of retention of the negatively charged amino acid residues, and the differences between the two classification methods were also compared.ResultsAmong 236 patients, the CALR gene type 1 or type 2 mutation was detected in 206 cases (87.3%), including 173 ET patients (99 cases of type 1 mutation and 74 cases of type 2 mutation) and 33 PMF patients (28 cases of type 1 mutation and 5 cases of type 2 mutation). The CALR non-type 1 or non-type 2 mutation was detected in 30 cases, including 25 ET patients and 5 PMF patients. Among 173 ET patients with CALR gene mutation, the white blood cell count (WBC) of patients with type 1 mutation was higher than that of patients with type 2 mutation [(8.6±2.7)×109/L vs. (7.6±2.4)×109/L, t = 2.45, P = 0.015]. Among 33 PMF patients with CALR gene mutation, the age of patients with type 1 mutation was older than that of patients with type 2 mutation [(58±13) years old vs. (41±16) years old, t = 2.51, P = 0.018]. According to the α-helix propensity score of mutant protein peptide chain and the degree of retention of the negatively charged amino acid residues, 27 kinds of non-type 1 or non-type 2 mutations were classified by using sequencing method, and there were differences between the two methods. According to the α-helix propensity score of the mutant protein peptide chain, the proportion of type 1/type 1-like mutation in PMF patients was higher than that in ET patients [78.9% (30/38) vs. 56.6% (112/198), P < 0.01]. According to the degree of retention of negatively charged amino acid residues in the mutant protein peptide chain, the isoelectric point (pI) value of the mutant protein peptide chain was higher than that of the wild type sequence. The pI value of the type 1-like mutant protein peptide chain was higher than that of the type 2-like mutation (11.79±0.15 vs. 10.02±0.42, t = 11.51, P < 0.01).ConclusionsType 1 mutated ET patients may be closely related to the high risk of myelofibrosis transformation. The results of the classification of CALR mutations are different according to the α-helix propensity score of the mutant protein peptide chain and the degree of retention of the negatively charged amino acid residues. Further study is necessary to identify the pathogenesis of MPN caused by CALR mutation, and to determine the relationship between mutation type and prognosis of disease.Key words: Myeloproliferative neoplasms; Calreticulin; Thrombocythemia, essential; Primary myelofibrosis; Mutation; DNA mutational analysis" @default.
• W3029619171 created "2020-06-05" @default.
• W3029619171 creator A5015860750 @default.
• W3029619171 creator A5021925661 @default.
• W3029619171 date "2019-11-25" @default.
• W3029619171 modified "2023-09-24" @default.
• W3029619171 title "Significance of calreticulin gene mutations classification in BCR-ABL1 negative myeloproliferative neoplasms" @default.
• W3029619171 doi "https://doi.org/10.3760/cma.j.issn.1009-9921.2019.11.001" @default.
• W3029619171 hasPublicationYear "2019" @default.
• W3029619171 type Work @default.
• W3029619171 sameAs 3029619171 @default.
• W3029619171 citedByCount "0" @default.
• W3029619171 crossrefType "journal-article" @default.
• W3029619171 hasAuthorship W3029619171A5015860750 @default.
• W3029619171 hasAuthorship W3029619171A5021925661 @default.
• W3029619171 hasConcept C104317684 @default.
• W3029619171 hasConcept C126322002 @default.
• W3029619171 hasConcept C153911025 @default.
• W3029619171 hasConcept C158617107 @default.
• W3029619171 hasConcept C176944494 @default.
• W3029619171 hasConcept C2778837598 @default.
• W3029619171 hasConcept C2780007613 @default.
• W3029619171 hasConcept C2780076729 @default.
• W3029619171 hasConcept C2781057849 @default.
• W3029619171 hasConcept C2994225774 @default.
• W3029619171 hasConcept C36823959 @default.
• W3029619171 hasConcept C47450691 @default.
• W3029619171 hasConcept C49105822 @default.
• W3029619171 hasConcept C501734568 @default.
• W3029619171 hasConcept C502942594 @default.
• W3029619171 hasConcept C50524450 @default.
• W3029619171 hasConcept C54355233 @default.
• W3029619171 hasConcept C71924100 @default.
• W3029619171 hasConcept C76818968 @default.
• W3029619171 hasConcept C86803240 @default.
• W3029619171 hasConceptScore W3029619171C104317684 @default.
• W3029619171 hasConceptScore W3029619171C126322002 @default.
• W3029619171 hasConceptScore W3029619171C153911025 @default.
• W3029619171 hasConceptScore W3029619171C158617107 @default.
• W3029619171 hasConceptScore W3029619171C176944494 @default.
• W3029619171 hasConceptScore W3029619171C2778837598 @default.
• W3029619171 hasConceptScore W3029619171C2780007613 @default.
• W3029619171 hasConceptScore W3029619171C2780076729 @default.
• W3029619171 hasConceptScore W3029619171C2781057849 @default.
• W3029619171 hasConceptScore W3029619171C2994225774 @default.
• W3029619171 hasConceptScore W3029619171C36823959 @default.
• W3029619171 hasConceptScore W3029619171C47450691 @default.
• W3029619171 hasConceptScore W3029619171C49105822 @default.
• W3029619171 hasConceptScore W3029619171C501734568 @default.
• W3029619171 hasConceptScore W3029619171C502942594 @default.
• W3029619171 hasConceptScore W3029619171C50524450 @default.
• W3029619171 hasConceptScore W3029619171C54355233 @default.
• W3029619171 hasConceptScore W3029619171C71924100 @default.
• W3029619171 hasConceptScore W3029619171C76818968 @default.
• W3029619171 hasConceptScore W3029619171C86803240 @default.
• W3029619171 hasIssue "11" @default.
• W3029619171 hasLocation W30296191711 @default.
• W3029619171 hasOpenAccess W3029619171 @default.
• W3029619171 hasPrimaryLocation W30296191711 @default.
• W3029619171 hasRelatedWork W1529774782 @default.
• W3029619171 hasRelatedWork W1693782387 @default.
• W3029619171 hasRelatedWork W19465474 @default.
• W3029619171 hasRelatedWork W2008135652 @default.
• W3029619171 hasRelatedWork W2012591885 @default.
• W3029619171 hasRelatedWork W2045203627 @default.
• W3029619171 hasRelatedWork W2394898621 @default.
• W3029619171 hasRelatedWork W2401993180 @default.
• W3029619171 hasRelatedWork W2407645504 @default.
• W3029619171 hasRelatedWork W2408049385 @default.
• W3029619171 hasRelatedWork W2556518047 @default.
• W3029619171 hasRelatedWork W2588905497 @default.
• W3029619171 hasRelatedWork W2588972822 @default.
• W3029619171 hasRelatedWork W2595384297 @default.
• W3029619171 hasRelatedWork W2898564839 @default.
• W3029619171 hasRelatedWork W2945325076 @default.
• W3029619171 hasRelatedWork W2980400495 @default.
• W3029619171 hasRelatedWork W2992886705 @default.
• W3029619171 hasRelatedWork W3029716211 @default.
• W3029619171 hasRelatedWork W3030811461 @default.
• W3029619171 hasVolume "28" @default.
• W3029619171 isParatext "false" @default.
• W3029619171 isRetracted "false" @default.
• W3029619171 magId "3029619171" @default.
• W3029619171 workType "article" @default.